GSK plc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while YieldMax NVDA Option Income Strategy ETF trades at $13.08. The key difference: GSK plc pays a 3.57% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and GSK plc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GSK | NVDY | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $17.96 |
52-Week Low | $38.22 | $11.58 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $13.06, up 2.59% today with a bullish technical signal. The ETF generates weekly dividend distributions through options strategies on NVIDIA stock, though recent news highlights concerns about opportunity cost versus direct NVIDIA ownership. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while moving averages remain bullish.
The outlook balances high income generation against capped upside potential. Investment opportunity lies in consistent weekly distributions, while primary risks include underperformance versus NVIDIA's explosive growth and the fund's strategy of selling call options that limit participation in NVIDIA's strongest rallies. The ETF appeals to income-focused investors willing to trade growth potential for regular cash flow.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →